INTS Live signals | Maximize Profits with Getagraph.com

BUY 123295 min ago

@ $3.41

Issued: 12 Feb 2024 @ 14:19

Return: 10.56%

Previous signal: Feb 8 - 12:41

Previous signal: Sell

Return: -5.28 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:00):

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
Today's Volume	1 728.00
Average Volume	41 103.00
Market Cap	51.68M
EPS	$0 ( 2024-04-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.73
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)
2024-03-06	Leahy Emer	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Goldberg Mark A	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Donovan Daniel	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Bender Lewis H	Buy	464 805	Stock Option (right to buy Common Stock)

INSIDER POWER
57.37
Last 23 transactions
Buy: 803 379 \| Sell: 331 500

Intensity Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intensity Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
Revenue:	$0
Gross Profit:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
Revenue:	$0
Gross Profit:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.